Patents Examined by Bong-Sook Baek
  • Bupropion as a modulator of drug activity
    Patent number: 11524007
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: April 11, 2022
    Date of Patent: December 13, 2022
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 11517542
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: April 15, 2022
    Date of Patent: December 6, 2022
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 11510918
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: April 4, 2022
    Date of Patent: November 29, 2022
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Prodrug compositions
    Patent number: 11498933
    Abstract: The present invention provides a composition comprising nanoparticles of prodrugs of certain pharmaceutically active agents, wherein the nanoparticles of prodrugs are dispersed within a carrier material. The present invention further provides processes for the making of the same.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: November 15, 2022
    Assignees: The John Hopkins University
    Inventors: Steven Paul Rannard, Andrew Owen, Paul Curley, James Hobson, Marco Siccardi, Caren L. Freel Meyers, Amer Al-Khouja, David J. Meyers, Charles Williams Flexner
  • Bupropion as a modulator of drug activity
    Patent number: 11497721
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: April 4, 2022
    Date of Patent: November 15, 2022
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Extended release compositions comprising pyridostigmine
    Patent number: 11478425
    Abstract: Extended release pyridostigmine dosage forms, suitable for maintaining stable plasma concentrations with reduced or minimized initial burst release/dose dumping of pyridostigmine, are provided. The dosage forms include matrix tablets, gastroretentive tablets, and pellets, the latter being suitable for dosing in capsules, tablets, and sachets, as well as for sprinkling on foodstuffs. The disclosure also provides methods for improving patient compliance by administering once-a-day extended release pyridostigmine bromide dosage forms that provide a superior controlled drug release.
    Type: Grant
    Filed: January 20, 2021
    Date of Patent: October 25, 2022
    Assignee: Amneal Complex Products Research LLC
    Inventors: Namdev B. Shelke, Siva Ram Kiran Vaka, Dipen Desai, Wantanee Phuapradit, Navnit H. Shah
  • Bupropion as a modulator of drug activity
    Patent number: 11478468
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 28, 2022
    Date of Patent: October 25, 2022
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 11439636
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: August 18, 2021
    Date of Patent: September 13, 2022
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Heterocyclylamines as PI3K inhibitors
    Patent number: 11433071
    Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: September 6, 2022
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Wenqing Yao, Andrew P. Combs, Eddy W. Yue, Song Mei, Joseph Glenn, Thomas P. Maduskuie, Jr., Richard B. Sparks, Brent Douty, Chunhong He
  • Bupropion as a modulator of drug activity
    Patent number: 11426401
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: August 30, 2022
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 11419867
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: November 22, 2021
    Date of Patent: August 23, 2022
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • STAT3 phosphorylation during graft-versus-host disease
    Patent number: 11406707
    Abstract: Compositions and methods to reduce the risk of graft versus host disease (GVHD) in a subject receiving hematopoietic stem cell transplantation (HSCT). Also disclosed are methods for identifying patients receiving HSCT who are at risk for developing GVHD, methods for prognosing the severity of GVHD in a subject receiving HSCT, and methods for monitoring efficacy of a therapeutic for treatment of GVHD in a subject HSCT.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: August 9, 2022
    Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
    Inventor: Brian Betts
  • Fragrance compositions and methods of use thereof
    Patent number: 11384312
    Abstract: A fragrance composition comprising one or more fragrance compounds for use in reducing or inhibiting a subject's physiological reaction to stress is disclosed. The composition can be incorporated into various consumer end products.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: July 12, 2022
    Assignee: TAKASAGO INTERNATIONAL CORPORATION
    Inventors: Bruno Leyssene, Louis J. Lombardo, Raphael K. L. Kang, Alba T. Cilia
  • Polymer
    Patent number: 11382854
    Abstract: A polymer having the following monomers in polymerized form (in weight %): A) 49-60% of a first monomer which is selected from the group consisting of methyl acrylate, methyl methacrylate, ethyl acrylate, ethyl methacrylate, C3-alkyl acrylate, C3-alkyl methacrylate, C4-alkyl acrylate, C4-alkyl methacrylate and mixtures thereof, B) 30-40% methacrylic acid, C) 4-15% acrylic acid, and D) 0.02-0.30% of a crosslinking agent having at least two allyl moieties, wherein the sum of the amounts of monomers A to D is 100%. A hair styling composition containing the polymer and use of the polymer or of the hair styling composition for styling hair also are disclosed.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: July 12, 2022
    Assignees: BASF SE, BASF Interservicios S.A. de C.V., BASF ESPANOLA S.L., BASF PLC
    Inventors: Peter Hoessel, Christian Schade, Cristina Amela, Bianca Seelig, Andrea Tomlinson, Volker Wendel, Rolf Werner, Luis Angel Ibarra
  • Bupropion as a modulator of drug activity
    Patent number: 11382874
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: November 24, 2021
    Date of Patent: July 12, 2022
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Topical pharmaceutical formulation
    Patent number: 11376213
    Abstract: There is described a topical composition for application of an NSAID comprising ibuprofen, the composition comprising a solution or suspension of the NSAID as active ingredient in a residual carrier system comprising a polyhydric alcohol, a glycol ether, an ester of a higher fatty acid and optionally water, the ingredients of the residual carrier system having the following concentrations in percentages by weight: polyhydric alcohol 50-90 glycol ether 7.5-40 ester 0.5-5 water optional in which either the composition or the residual phase is in a single phase under ambient conditions and the maximum water concentration is that above which the composition or the residual phase exhibits signs of inhomogeneity.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: July 5, 2022
    Assignee: FUTURA MEDICAL DEVELOPMENTS LIMITED
    Inventors: Adrian Davis, Marc Barry Brown
  • Aqueous suspension suitable for oral administration
    Patent number: 11369567
    Abstract: The present invention provides liquid oral dosage form of lipid lowering agent suitable for oral administration to human or animals.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: June 28, 2022
    Assignee: LIQMEDS WORLDWIDE LIMITED
    Inventors: Sandip P. Mehta, Henil Alpeshbhai Patel, Jayanta Kumar Mandal
  • Bupropion as a modulator of drug activity
    Patent number: 11311534
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: April 26, 2022
    Assignee: ANTECIP BIO VENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 11298352
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: March 15, 2021
    Date of Patent: April 12, 2022
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Bupropion as a modulator of drug activity
    Patent number: 11298351
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: November 11, 2020
    Date of Patent: April 12, 2022
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau